铂类抗癌药物展望  

Future Development of Platinum Anticancer Drugs

作　　者：刘伟平[1] 张永俐[1] 孙加林[1] 

机构地区：[1]昆明贵金属研究所金属药物研究室,昆明云南650221

出　　处：《贵金属》2005年第1期47-52,共6页Precious Metals

基　　金：云南省人才培引项目资助(2003RC06)。

摘　　要：在过去的10年里,铂类抗癌药物取得了重要的进展,又有4种新药,奈达铂、奥沙利铂、舒铂和洛铂相继于1995～2001年成功上市,同时也有多个候选药物因疗效低、毒性大,与顺铂、卡铂比较无优势而在临床试验中被淘汰.目前还有另外9种铂化合物仍在进行临床研究,这些化合物为顺铂和卡铂的类似物、亲脂性配合物、口服铂(Ⅳ)配合物、多核铂配合物以及具有空间位阻的铂配合物.新的铂类抗癌药将在今后10～20年内从那些在临床研究中显示出低毒性、抗癌谱广、与现有药物无交叉耐药性的化合物中产生.The past 10 years have witnessed important progress in platinum anticancer drugs. Four new drugs, Nedaplatin and Oxaliplatin and Sunpla and Lobaplatin,were successfully commercialized in 1995, 1996, 1999 and 2001, respectively. Several new candidate compounds were abandoned during the clinical trials due to low efficiency or/and high toxicity or/and no advantages over Cisplatin and Carboplatin. Another 9 platinum compounds are being still clinically tested worldwide. These include the analogues of Cisplatin and Carboplatin, the lipophilic complexes, the oral Pt(Ⅳ) complexes,the multinuclear complexes and the sterically hindered complex. The new anticancer platinum drugs will be developed in 10～20 years from these Pt compounds showing reduction in toxicity, increased spectrum and no cross-resistance with the existing anticancer drugs in the clinical research.

关 键 词：铂类抗癌药 药物 卡铂 顺铂 临床研究 奈达铂 抗癌谱 淘汰 交叉耐药性 低毒性 

分 类 号：TG146[一般工业技术—材料科学与工程] R979.1[金属学及工艺—金属材料]